Revenues, Significant Customers and Concentrations of Risk

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Revenues, Significant Customers and Concentrations of Risk

4. Revenues, Significant Customers and Concentrations of Risk

The following table presents the Company’s revenue on a disaggregated basis by types of goods and services and major product lines:

	Three months ended March 31,
	2020		2019
Proprietary product sales	$	12,566	$	4,771
Partnered product sales		14,531		13,529
Total product revenue		27,097		18,300
Licensing and development revenue		1,755		915
Royalties		4,227		4,071
Total revenue	$	33,079	$	23,286

Revenues disaggregated by customer location are as follows: 

	Three Months Ended
	March 31,
	2020		2019
United States of America	$	32,470	$	21,185
Europe		609		2,090
Other		—		11
	$	33,079	$	23,286

The following table identifies customers from which the Company derived 10% or more of its total revenue in any of the periods presented:

	Three Months Ended
	March 31,
	2020	2019
Teva	42%	46%
AMAG	16%	20%
AmerisourceBergen Corporation	12%	<10%
McKesson Corporation	11%	<10%
Cardinal Health	10%	<10%
Ferring	<10%	13%